Rockefeller Capital Management L.P. Revance Therapeutics, Inc. Transaction History

Rockefeller Capital Management L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	SELL	$18.32 - $30.66 $17,312 - $28,973	-945 Reduced 90.43%	100 $1,000
Q3 2022 Nov 02, 2022	BUY	$14.33 - $28.47 $5,817 - $11,558	406 Added 63.54%	1,045 $28,000
Q2 2022 Aug 12, 2022	BUY	$11.52 - $20.4 $6,842 - $12,117	594 Added 1320.0%	639 $8,000
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $5,881 - $13,154	-472 Reduced 91.3%	45 $0
Q1 2021 May 11, 2021	BUY	$24.03 - $29.97 $12,423 - $15,494	517 New	517 $14,000
Q4 2020 Feb 12, 2021	SELL	$23.41 - $28.34 $7,350 - $8,898	-314 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$23.23 - $34.3 $2,671 - $3,944	115 Added 57.79%	314 $7,000
Q2 2020 Aug 12, 2020	SELL	$12.6 - $26.55 $1,335 - $2,814	-106 Reduced 34.75%	199 $5,000
Q1 2020 May 12, 2020	BUY	$12.46 - $27.81 $3,800 - $8,482	305 New	305 $5,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.